Ipr-2025

Ipr-2025

AOB11481

CAS 1008664-84-3

More details

1000 Items

$0.00

Overview

Novel inhibitor of glioblastoma multiforme (GBM), inhibiting cell viability of low-passage patient-derived GBM spheroids, blocking tube-formation of endothelial cells in Matrigel, showing no effect on primary hematopoietic CD34+ progenitor spheroids or astrocyte cell viability